Protagonist Therapeutics Quick Ratio 2015-2022 | PTGX

Historical quick ratio values for Protagonist Therapeutics (PTGX) over the last 10 years.
Protagonist Therapeutics Quick Ratio Historical Data
Date Current Assets - Inventory Current Liabilities Quick Ratio
2022-03-31 $0.00B $0.04B 0.00
2021-12-31 $0.00B $0.04B 0.00
2021-09-30 $0.00B $0.04B 0.00
2021-06-30 $0.00B $0.04B 0.00
2021-03-31 $0.00B $0.04B 0.00
2020-12-31 $0.00B $0.04B 0.00
2020-09-30 $0.00B $0.04B 0.00
2020-06-30 $0.00B $0.04B 0.00
2020-03-31 $0.00B $0.04B 0.00
2019-12-31 $0.00B $0.04B 0.00
2019-09-30 $0.00B $0.03B 0.00
2019-06-30 $0.00B $0.03B 0.00
2019-03-31 $0.00B $0.02B 0.00
2018-12-31 $0.00B $0.03B 0.00
2018-09-30 $0.00B $0.02B 0.00
2018-06-30 $0.00B $0.03B 0.00
2018-03-31 $0.00B $0.03B 0.00
2017-12-31 $0.00B $0.04B 0.00
2017-09-30 $0.00B $0.05B 0.00
2017-06-30 $0.00B $0.01B 0.00
2017-03-31 $0.00B $0.01B 0.00
2016-12-31 $0.00B $0.01B 0.00
2016-09-30 $0.00B $0.01B 0.00
2016-06-30 $0.00B $0.00B 0.00
2016-03-31 $0.00B 0.00
2015-12-31 $0.00B 0.00
2015-09-30 $0.00B 0.00
2015-06-30 $0.00B 0.00
2014-12-31 $0.00B $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.375B $0.027B
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $164.215B 9.99
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.343B 16.33
Biohaven Pharmaceutical Holding (BHVN) United States $10.057B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.540B 0.00
Emergent Biosolutions (EBS) United States $1.675B 7.17
Arcus Biosciences (RCUS) United States $1.287B 32.64
Myovant Sciences (MYOV) United Kingdom $0.927B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.347B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.113B 23.10
SQZ Biotechnologies (SQZ) United States $0.094B 0.00